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BIOKIT 
BIOKIT IS A BARCELONA FIRM THAT DOES RESEARCH INTO 
REAGENTS FOR CLINICAL DIAGNOSIS, AS WELL AS DEVELOPING 
AND MANUFACTURING THEM. IT PRESENTED ONE OF THE FIRST 
PROJECTS IN BIOTECHNOLOGY TO BE APPROVED UNDER THE 
EUREKA PROGRAMME. 
JOAN C U A D R . A S  T E C H N I C A L  D I R E C T O R  O F  B I O K I T  
he development of simple, reli- 
able methods for the diagnosis 
of human diseases is of obvious 
importance for health. Kits containing 
sets of reagents and methods for easy 
diagnosis are one aspect of this. Biokit 
S.A. is a Barcelona firm that does re- 
search into reagents for clinical diagno- 
sis, as well as developing and manufac- 
turing them. It is primarily concerned 
with sexually related ailments, mental 
deficiency and aging, and its main pro- 
ducts are designed for pregnancy tes- 
ting, and for diagnosing the rheumatoid 
factor and various other human disea- 
ses, particularly sexually transmitted di- 
seases like syphilis and chlamydia. 
The products are distributed in kit-form 
in Spain and are sold in bulk to other 
countries -Western Europe, the Middle 
East, the United States and Japan- 
where distributors include them in kits of 
their own. The Spanish market is small 
and the firm is able to finance its re- 
search activities through exports. Biokit 
considers it is  working in a world market 
worth at least 1,000 million pesetas 
(over $7 million). In the field of medical 
diagnosis, the quality of the product is 
of the utmost importance. For this rea- 
son, one whole department at Biokit is 
responsible for quality control through 
coordination of the different depart- 
ments and by ensuring that production 
practices are in line with the particularly 
strict standards in force in the United 
States. Biokit undergoes periodic ins- 
pections by the U.S. Food and Drugs 
Administration. 
Medical diagnosis is a market in which 
scientific and technological progress is 
extremely fast, and in order to maintain 
growth, firms must keep constantly up to 
date with new technological discoveries 
and techniques for diagnosing disease. 
It is vital to be in touch with the world 
market in order to keep abreast of new 
scientific and technical discoveries and 
observe the movements of the large 
multinational companies. The very survi- 
val of the firm is the main reason why 
Biokit is so determined to innovate. In a 
market where technology is constantly 
changing, it is  necessarily dependent on 
innovation since without it its products 
would soon become obsolete. At the 
same time Biokit carries out a programme 
of growth aimed at extending its ran- 
ge of products. It is currently engaged 
in virological research to develop ways 
of diagnosing German measles, he- 
patitis, the cytomegalovirus and the 
herpes virus. Another project in bacte- 
riology and parasitology is  concerned 
with the diagnosis of syphilis and toxo- 
plasmosis and the grouping of germs 
including the streptococcus, meningo- 
coccus and staphylococcus. 
Biokit has a staff of eighty, with an ave- 
rage age of thirty-two. Eighteen of them 
work in the Research and Development 
Department, 70 % are university gra- 
duates and many have master's de- 
grees or Ph.D.s. The firm invests 15 % of 
its sales revenue in research and deve- 
lopment. The capital is 100 % Spanish 
and none of the products are manufac- 
tured under licence. Work began in 
1980 with research into monoclonal an- 
tibodies and since 1985 three resear- 
chers have been working on the deve- 
lopment of DNA probes. Researchers in 
Spain face considerably greater obsta- 
cles than those in countries with more 
advanced technology. Foremost among 
them are the insufficient support private 
enterprise receives from universities, 
the lack of research personnel, the low 
professional standards of many consul- 
tants and difficulties in obtaining infor- 
mation. To overcome these problems, 
Biokit has been cooperating with a num- 
ber of foreign research organizations, 
mostly in the United States and France, 
and has been particularly keen to secure 
training for its staff in top research 
centres. A recently launched project in- 
volves sending Biokit researchers to do 
joing research into new products in these 
foreign centres for periods of one to 
three years. Certain projects have also 
got under way with other Spanish labo- 
ratories. On 6 November 1985 the EEC 
Council of Ministers approved the first 
ten projects to be undertaken within the 
EUREKA programme. One of these, the 
development of a kit for direct diagno- 
sis of gonorrhea, was presented by Bio- 
kit and PA Technology. The fact that this 
was one of the first projects in biotech- 
nology to be approved under the new 
European research programme and the 
first in which the main participant was a 
Spanish company is further proof of 
Biokit's commitment to the industrial ap- 
plications of new technologies. 
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